Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis

Inclusion Criteria (main): * ECOG Performance Status of 0, 1 or 2 * Histologically or cytologically confirmed liver metastases of uveal melanoma * At least one measurable lesion according to RECIST criteria v1.1 determined MRI (if contraindications against MRI exist CT with contrast media can is allowed) * Metastases in other sides are allowed if not in need of treatment (e.g. asymptomatic bone metastasis without indication for radiation) * Prior treatment with systemic anti-cancer therapy is allowed if terminated ≥ 4 weeks prior to study treatment start and recovery from toxicity is achieved * Surgery in general and hepatic surgery in particular (e.g. lobe resection, radiofrequency ablation) prior to study enrollment are allowed if realized ≥ 4 weeks prior to study enrollment and recovery from surgery is achieved Exclusion Criteria (main): * Surgically treatable liver metastases * Previous intraarterial hepatic treatment (e.g. radioembolisation, chemoembolisation, intraarterial chemotherapy, isolated or percutaneous hepatic perfusion) * Previous treatment with external liver radiation * Major intrahepatic occlusion of the portal vein and/or tumor infiltration of the portal vein * Liver cirrhosis Child-Pugh C * Progressive liver failure * Renale failure, bone marrow insufficiency, coagulopathy * Uncontrolled or severe medical conditions which could impair the ability to participate in the trial such as unstable cardiac disease or uncontrolled infection * Other malignancy and/or metastases in need of treatment * Current treatment with any anti-cancer therapy